Soyasaponin Ab
(Synonyms: 大豆皂苷Ab) 目录号 : GC37671
Soyasaponin Ab 是一种大豆皂苷，在 3T3-L1 脂肪细胞中通过下调 PPARγ 产生抗肥胖作用。
Cas No.:118194-13-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Soyasaponin Ab is a soyasaponin that exerts an anti-obesity effect in 3T3-L1 adipocytes through downregulation of peroxisome proliferator-activated receptor γ (PPARγ)[1].
[1]. Yang SH, et al. Soyasaponins Aa and Ab exert an anti-obesity effect in 3T3-L1 adipocytes through downregulation of PPARγ. Phytother Res. 2015 Feb;29(2):281-7.
| Cas No. | 118194-13-1 | SDF | |
| 别名 | 大豆皂苷Ab | ||
| 分子式 | C67H104O33 | 分子量 | 1437.52 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.6956 mL | 3.4782 mL | 6.9564 mL |
| 5 mM | 0.1391 mL | 0.6956 mL | 1.3913 mL |
| 10 mM | 0.0696 mL | 0.3478 mL | 0.6956 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Soyasaponin Ab ameliorates colitis by inhibiting the binding of lipopolysaccharide (LPS) to Toll-like receptor (TLR)4 on macrophages
J Agric Food Chem 2011 Dec 28;59(24):13165-72.PMID:22060784DOI:10.1021/jf2033818.
Many clinical studies have shown that daily intake of soybean [ Glycine max (L.) Merr., Fabacease] or its foods may reduce the risk of osteoporosis, heart attack, hyperlipidemia, coronary heart disease, cardiovascular and chronic renal diseases, and cancers, including prostate, colon, and breast cancers. Of the soy constituents, soyasaponins exhibit anti-aging, antioxidant, apoptotic, and anti-inflammatory effects. However, the anti-inflammatory effect of Soyasaponin Ab has not been thoroughly studied. Therefore, we investigated its anti-inflammatory effects in 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitic mice and lipopolysaccharide (LPS)-stimulated peritoneal macrophages. Soyasaponin Ab inhibited colon shortening, myeloperoxidase activity, the expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), and activation of the transcription factor nuclear factor-κB (NF-κB). Soyasaponin Ab (1, 2, 5, and 10 μM) inhibited the production of NO (IC(50) = 1.6 ± 0.1 μM) and prostaglandin E(2) (IC(50) = 2.0 ± 0.1 ng/mL), the expression of tumor necrosis factor (TNF)-α (IC(50) = 1.3 ± 0.1 ng/mL), interleukin (IL)-1β (IC(50) = 1.5 ± 0.1 pg/mL), and toll-like receptor (TLR)4, and the phosphorylation of interleukin-1 receptor-associated kinase (IRAK)-1 in LPS-stimulated peritoneal macrophages. Soyasaponin Ab weakly inhibited the phosphorylation of ERK, JNK, and p38. Soyasaponin Ab significantly reduced the binding of Alexa-Fluor-594-conjugated LPS to peritoneal macrophages. Soyasaponin Ab did not affect TLR4 expression or LPS-induced NF-κB activation in TLR4 siRNA-treated peritoneal macrophages (knockdown efficiency of TLR4 > 94%). On the basis of these findings, Soyasaponin Ab may ameliorate colitis by inhibiting the binding of LPS to TLR4 on macrophages.
Soyasaponin Ab inhibits lipopolysaccharide-induced acute lung injury in mice
Int Immunopharmacol 2016 Jan;30:121-128.PMID:26672918DOI:10.1016/j.intimp.2015.12.001.
Soyasaponin Ab (SA) has been reported to have anti-inflammatory effect. However, the effects of SA on lipopolysaccharide (LPS)-induced acute lung injury (ALI) have not been reported. The aim of this study was to investigate the anti-inflammatory effects of SA on LPS-induced ALI and clarify the possible mechanism. The mice were stimulated with LPS to induce ALI. SA was given 1h after LPS treatment. 12h later, lung tissues were collected to assess pathological changes and edema. Bronchoalveolar lavage fluid (BALF) was collected to assess inflammatory cytokines and nitric oxide (NO) production. In vitro, mice alveolar macrophages were used to investigate the anti-inflammatory mechanism of SA. Our results showed that SA attenuated LPS-induced lung pathological changes, edema, the expression of cycloxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) in lung tissues, as well as TNF-α, IL-6, IL-1β, and NO production in mice. Meanwhile, SA up-regulated the activities of superoxide dismutase (SOD) and catalase decreased by LPS in mice. SA also inhibited LPS-induced TNF-α, IL-6 and IL-1β production as well as NF-κB activation in alveolar macrophages. Furthermore, SA could activate Liver X Receptor Alpha (LXRα) and knockdown of LXRα by RNAi abrogated the anti-inflammatory effects of SA. In conclusion, the current study demonstrated that SA exhibited protective effects against LPS-induced acute lung injury and the possible mechanism was involved in activating LXRα, thereby inhibiting LPS-induced inflammatory response.
Evaluation of cytotoxicity and immune modulatory activities of Soyasaponin Ab: an in vitro and in vivo study
Phytomedicine 2014 Nov 15;21(13):1759-66.PMID:25444444DOI:10.1016/j.phymed.2014.09.002.
To improve the immune efficacy of protein subunit vaccines, novel adjuvants are needed to elicit a suitable protective immune response and to promote long term immunologic memory. In this work, Soyasaponin Ab, a major constituent among group A soyasaponins in soybeans was purified and prepared from soy hypocotyls. The immunomodulatory effects of Soyasaponin Ab both in vitro and in vivo were investigated, and its pro-immunomodulatory molecular mechanism was also studied. For in vitro assays, with mouse macrophage cell line RAW264.7 as the studying model, both cytotoxicity and immune stimulatory activity were investigated to evaluate the potential of Soyasaponin Ab as the vaccine adjuvant. The results indicated that Soyasaponin Ab could be significantly safer than Quillaja saponins (QS). Soyasaponin Ab showed no toxicities over the tested concentration ranges compared to QS. Soyasaponin Ab was proved able to promote releases of inflammatory cytokines like TNFα and IL-1β in a dose-dependent manner. Furthermore, NF-κB signalling was also activated by Soyasaponin Ab effectively. In addition, with TLR4 gene expression of RAW264.7 cell inhibited by RNA interference, immune stimulatory effects by Soyasaponin Ab dropped down significantly. On the other hand, the in vivo experiment results showed that anti-ovalbumin (OVA) IgG, IgG1, IgG2a, IgG2b were significantly enhanced by the Soyasaponin Ab and QS groups (p<0.05 or p<0.01). The results suggested that compared to QS, Soyasaponin Ab may represent a viable candidate for effective vaccine adjuvant. TLR4 receptor dependent pathway may be involved in immune stimulatory effects of Soyasaponin Ab.
Germinated soy germ with increased Soyasaponin Ab improves BMP-2-induced bone formation and protects against in vivo bone loss in osteoporosis
Sci Rep 2018 Aug 28;8(1):12970.PMID:30154422DOI:10.1038/s41598-018-31118-w.
Osteoporosis is frequently induced following menopause, and bone fractures result in serious problems including skeletal deformity, pain, and increased mortality. Therefore, safe and effective therapeutic agents are needed for osteoporosis. This study aimed to clarify the bone protecting effects of germinated soy germ extracts (GSGE) and their mode of action. GSGE increased expression of alkaline phosphatase (ALP) and osteocalcin (OCL) by stimulating the expression of runt-related transcription factor 2 (Runx2) and osterix (Osx) through activation of Smad signaling molecules. Furthermore, germination of soy germ increased levels of nutritional components, especially Soyasaponin Ab. The anabolic activity of Soyasaponin Ab in GSGE was also evaluated. GSGE and Soyasaponin Ab significantly protected against ovariectomy (OVX)-induced bone loss and improved bone-specific alkaline phosphatase (BALP) level in mouse serum. These in vitro and in vivo study results demonstrated that GSGE and Soyasaponin Ab have potential as therapeutic candidate agents for bone protection in postmenopausal osteoporosis.
Liquid chromatography/mass spectrometry-based structural analysis of Soyasaponin Ab metabolites by human fecal microflora
J Pharm Biomed Anal 2010 Sep 5;52(5):752-6.PMID:20207093DOI:10.1016/j.jpba.2010.02.011.
Soyasaponin Ab, a major constituent of soybean by human intestinal microflora, was anaerobically incubated with fecal suspensions from ten individuals for 48 h and its metabolites were measured by LC-MS/MS analysis. Ten metabolites were detected. The spectra of the parental constituent Soyasaponin Ab showed a peak at m/z 1435 [M-H](-) ion and those of its nine metabolites showed peaks at m/z 1310.0 [M-3C(2)H(2)O-H](-) ion, m/z 1267.9 [M-4C(2)H(2)O-H](-) ion, m/z 1105.3 [M-Glc-4C(2)H(2)O-H](-) ion, m/z 973.2 [M-Glc-Ara-4C(2)H(2)O-H](-) ion, m/z 943.4 [M-2Glc-4C(2)H(2)O-H](-) ion, m/z 811.1 [M-2Glc-Ara-4C(2)H(2)O-H](-) ion, m/z 781.2 [M-2Glc-Gal-4C(2)H(2)O-H](-) ion, m/z 649.0 [M-2Glc-Gal-Ara-4C(2)H(2)O-H](-) ion, and m/z 458.8 [Soyasapogenol A+H](+) ion. Metabolic activity varied significantly between individuals. The metabolic pathway was classified into two groups: the first group potently produced soyasapogenol A and the second group accumulated soyasapogenol A 3-beta-D-glucuronide.